Lifecore Biomedical

LFCR · NASDAQ

$6.37−$0.02 (−0.31%)TodayMarket closed ·
Prev close $6.39

Key indicators

LFCR profitability and balance sheet ratios

EPS -$0.1638 in Q1 FY27.

EPS by quarter
PeriodEPS
Q2 FY25-$0.526
Nov 2024-$0.1912
Q3 FY25-$0.3989
Q1 FY25-$0.031
Q2 FY26-$0.2671
Dec 2025-$0.4806
Q4 FY26-$0.3997
Q1 FY27-$0.1638

Where the money went

Q1 FY27, from revenue to net income

Lifecore Biomedical brought in $34.2M of revenue in Q1 FY27. It made a net loss of $7.1M.

Revenue
$34.2M
Costs, expenses and taxes
$41.3M
Net income
−$7.1M
Net margin
-20.9%

Income statement

Revenue and profit by reporting period

Revenue
Net income
LFCR income statement, quarterly
Line itemQ2 FY26Q4 FY26Q1 FY27
Revenue$31.1M$23.2M$34.2M
Gross profit$7.8M$4.5M$12.1M
Operating income−$3.1M−$4.7M$2.6M
Net income−$10.9M−$15.9M−$7.1M
Diluted EPS-$0.29-$0.43-$0.19

Balance sheet

What the company owns and owes at period end

Total assets
Total liabilities
LFCR balance sheet, quarterly
Line itemDec 2025Mar 2026Jun 2026
Total assets$232.2M$225.5M$229.5M
Total liabilities$198.1M$204.7M$213.4M
Shareholder equity$34.1M$20.8M$16.1M
Cash and short-term investments$17.5M$20.8M$17.2M
Total debt$142.2M$148.7M$155.1M

Cash flow

Cash in and out from operations, investing and financing

Operating
Investing
Financing
LFCR cash flow, quarterly
Line itemQ3 FY25Q2 FY26Q4 FY26
Operating cash flow$1.2M$1.8M$4.7M
Investing cash flow$1.5M−$1.7M−$1.1M
Financing cash flow−$6.8M−$1.4M−$0.3M
Capital expenditure−$5.5M−$1.7M−$1.1M
Free cash flow−$4.3M$0.0M$3.6M

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.